NASDAQ$OMCL

Omnicell Inc. · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Briefing

Omnicell reported Q4 2025 revenue of $314.0M with a GAAP loss of $0.05 per share and non-GAAP EPS of $0.40.

Fourth quarter total revenue rose 2% to $314.0 million on strength in technical services, SaaS/expert services, and consumables. GAAP net loss was $2.0 million ($(0.05) per diluted share) versus net income of $15.8 million a year ago; non-GAAP net income was $18.2 million ($0.40 per share). Annual recurring revenue grew to $635.6 million and product backlog was $640.3 million.

  • Q4 revenue $314.0M (+2% YoY); FY revenue $1.19B (+7%).
  • Non-GAAP EPS $0.40; ARR $635.6M (+9.6% YoY).
  • Launched Titan XT automated dispensing at ASHP Midyear.
  • FY26 guide: revenue $1.215B–$1.255B; non-GAAP EPS $1.65–$1.85.

Headline financials

Total Revenue

$314M

Previous: $307M+2.3%
EPS (adj)

$0.40

Previous: $0.60-33.3%
Non-GAAP EBITDA

$36.8M

Previous: $46.4M-20.7%
Non-GAAP gross margin

43.2%

Previous: 47.4%-8.9%
Non-GAAP operating margin

7.1%

Previous: 10.6%-33.0%
Non-GAAP EBITDA margin

11.7%

Previous: 15.1%-22.5%
Product bookings

$535M

Previous: $558M-4.1%
Annual Recurring Revenue

$636M

Previous: $580M+9.6%
Total product backlog

$640M

Previous: $646M-0.9%
Short-term product backlog

$435M

Previous: $447M-2.7%
Long-term product backlog

$205M

Previous: $199M+3.0%
Net Income

-$2.03M

Previous: $16M-112.7%
Operating Income

$415K

Previous: $21.8M-98.1%
Gross Profit

$130M

Previous: $142M-8.1%

Revenue & EPS history

Omnicell · Revenue · Quarterly

$314M

Q4 2025+2.3%vs Q4 2024
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Omnicell · $188M total across 1 segment · Q2 2023

  • Product revenues
    $188M-19.4%

Forward guidance

For 2026, Omnicell expects revenue of $1.215B–$1.255B, product bookings of $510M–$560M, ARR of $680M–$700M, and non-GAAP EPS of $1.65–$1.85 with non-GAAP EBITDA of $145M–$160M.

Tailwinds

  • FY26 ARR guide $680M–$700M supports recurring revenue mix.
  • Titan XT launch targets nursing workflow and enterprise ADS demand.
  • Q4 product backlog $640M provides visibility on installations.
  • No revolver balance; $350M availability on credit facility.

Headwinds

  • FY25 product bookings down 4% in late XT upgrade cycle.
  • Q4 GAAP net loss on higher opex and prior-year gain comparisons.
  • Tariff, cyber, and hospital capital budget risks in 2026 outlook.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+0.7%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+4.7%

Avg return

30 days after

55%

36 / 65 earnings

Positive

+34.3%

Q2 2024

Best reaction

-29.4%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.2%+13.7%+18.8%
Q4 2025-16.3%-16.5%-11.5%
Q3 2025+13.4%+16.7%+23.5%
Q1 2025-16.0%-15.4%+1.2%
Q4 2024-11.2%-7.1%-16.7%
Q3 2024+21.2%+20.9%+16.1%
Q2 2024+34.3%+41.6%+52.3%
Q1 2024+10.9%+11.5%+19.9%
Q4 2023-15.6%-11.9%-12.0%
Q3 2023-14.9%-13.9%-5.5%
Q2 2023+2.3%+2.9%-10.0%
Q1 2023+8.9%+7.1%+18.6%
Q4 2022+7.9%+6.6%+6.4%
Q3 2022-29.4%-35.9%-33.4%
Q2 2022-2.1%-5.6%-10.6%
Q1 2022+1.2%+5.9%+4.7%
Q4 2021-9.6%-18.4%-11.5%
Q3 2021+2.2%+1.6%+1.5%
Q2 2021-1.1%+0.4%+7.1%
Q1 2021+1.8%-1.5%-2.4%
Q4 2020+7.0%+8.9%+6.5%
Q3 2020+2.3%+2.9%+27.0%
Q2 2020+9.1%+5.5%+2.7%
Q1 2020-6.1%-12.3%-0.5%
Q4 2019-1.4%+2.3%-4.5%
Q3 2019-3.7%-1.9%+7.4%
Q2 2019+6.7%+5.4%+0.6%
Q1 2019+0.7%+3.8%+4.7%
Q4 2018+17.9%+21.0%+28.0%
Q3 2018+6.1%+15.2%+18.8%
Q2 2018+13.7%+13.0%+29.5%
Q1 2018+1.6%-0.1%+5.3%
Q4 2017-6.2%-9.8%-12.9%
Q3 2017-6.4%-8.2%-7.6%
Q2 2017+12.5%+16.3%+12.1%
Q1 2017-3.2%-1.7%+0.0%
Q4 2016-0.7%+1.0%+4.5%
Q3 2016-6.3%-6.8%+3.2%
Q2 2016+6.8%+4.7%+3.4%
Q1 2016+3.9%
Q4 2015-1.0%
Q3 2015-10.5%
Q2 2015-8.8%
Q1 2015-2.6%
Q4 2014+5.3%
Q3 2014+9.7%
Q2 2014-3.9%
Q1 2014+0.4%
Q4 2013+8.9%
Q3 2013-1.4%
Q2 2013+8.7%
Q1 2013+7.6%
Q3 2010-1.3%
Q4 2012+13.4%
Q3 2012+12.2%
Q2 2012+0.9%
Q1 2011-0.3%
Q1 2012+4.8%
Q4 2011+2.6%
Q4 2009+2.6%
Q3 2011-0.7%
Q2 2010-16.9%
Q2 2011-16.9%
Q4 2010-16.9%
Q1 2010+7.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro